Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 2. Psoriatic arthritis: Overview and guidelines of care for treatment with an emphasis on the biologics

Alice Gottlieb, Neil J. Korman, Kenneth B. Gordon, Steven R. Feldman, Mark Lebwohl, John Y.M. Koo, Abby S. Van Voorhees, Craig A. Elmets, Craig L. Leonardi, Karl R. Beutner, Reva Bhushan*, Alan Menter

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

328 Scopus citations

Abstract

Psoriasis is a common, chronic, inflammatory, multisystem disease with predominantly skin and joint manifestations affecting approximately 2% of the population. In this second of 5 sections of the guidelines of care for psoriasis, we give an overview of psoriatic arthritis including its cardinal clinical features, pathogenesis, prognosis, classification, assessment tools used to evaluate psoriatic arthritis, and the approach to treatment. Although patients with mild to moderate psoriatic arthritis may be treated with nonsteroidal anti-inflammatory drugs and/or intra-articular steroid injections, the use of disease-modifying antirheumatic drugs, particularly methotrexate, along with the biologic agents, are considered the standard of care in patients with more significant psoriatic arthritis. We will discuss the use of disease-modifying antirheumatic drugs and the biologic therapies in the treatment of patients with moderate to severe psoriatic arthritis.

Original languageEnglish (US)
Pages (from-to)851-864
Number of pages14
JournalJournal of the American Academy of Dermatology
Volume58
Issue number5
DOIs
StatePublished - May 1 2008

ASJC Scopus subject areas

  • Dermatology

Fingerprint Dive into the research topics of 'Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 2. Psoriatic arthritis: Overview and guidelines of care for treatment with an emphasis on the biologics'. Together they form a unique fingerprint.

Cite this